These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Benenson E; Fries JW; Heilig B; Pollok M; Rubbert A Clin Rheumatol; 2005 Jun; 24(3):251-7. PubMed ID: 15940558 [TBL] [Abstract][Full Text] [Related]
10. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204 [TBL] [Abstract][Full Text] [Related]
11. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Egan LJ; Sandborn WJ; Tremaine WJ Am J Gastroenterol; 1998 Mar; 93(3):442-8. PubMed ID: 9517654 [TBL] [Abstract][Full Text] [Related]
12. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ; Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314 [TBL] [Abstract][Full Text] [Related]
13. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial. Lindsay JO; Hind D; Swaby L; Berntsson H; Bradburn M; Bannur C U; Byrne J; Clarke C; Desoysa L; Dickins B; Din S; Emsley R; Foulds GA; Gribben J; Hawkey C; Irving PM; Kazmi M; Lee E; Loban A; Lobo A; Mahida Y; Moran GW; Papaioannou D; Parkes M; Peniket A; Pockley AG; Satsangi J; Subramanian S; Travis S; Turton E; Uttenthal B; Rutella S; Snowden JA Lancet Gastroenterol Hepatol; 2024 Apr; 9(4):333-345. PubMed ID: 38340759 [TBL] [Abstract][Full Text] [Related]
15. Open label trial of oral clarithromycin in active Crohn's disease. Leiper K; Morris AI; Rhodes JM Aliment Pharmacol Ther; 2000 Jun; 14(6):801-6. PubMed ID: 10848665 [TBL] [Abstract][Full Text] [Related]
17. Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited? Charpignon C; Beau P Gastroenterol Clin Biol; 2008 Feb; 32(2):153-7. PubMed ID: 18343615 [TBL] [Abstract][Full Text] [Related]
18. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Abreu MT; von Tirpitz C; Hardi R; Kaatz M; Van Assche G; Rutgeerts P; Bisaccia E; Goerdt S; Hanauer S; Knobler R; Mannon P; Mayer L; Ochsenkuhn T; Sandborn WJ; Parenti D; Lee K; Reinisch W; Inflamm Bowel Dis; 2009 Jun; 15(6):829-36. PubMed ID: 19130617 [TBL] [Abstract][Full Text] [Related]
19. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study. Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917 [TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn's disease. Hommes DW; Duijvestein M; Zelinkova Z; Stokkers PC; Ley MH; Stoker J; Voermans C; van Oers MH; Kersten MJ J Crohns Colitis; 2011 Dec; 5(6):543-9. PubMed ID: 22115372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]